Betting it achieved its other goal of temporarily gaming their stock price just fine, though.
This is so sad.I am now trying to quit using vape as a stimulant because it makes me sick and people around me disapprove,but I am going to invest in nootropics or brain health supplement
Do you think it’s a good step @shutterbug?
No more meds for negative…any other meds for negative inline beside this one?
KarXT maybe.
Ok thanks,will research abit.Btw, @everhopeful are you still on sarcosine mind asking?
I’ve never taken Sarcosine …
Wellbutrin and Abilify can work for negative symptoms. Abilify improved my negatives by 40%.
Oops,sorry my mistake…
I am researching on l theanine,people are posting that it relaxes you and are good for anxiety
Supplements aren’t as effective as psychiatric meds, I tried tons of supplements, nothing helped, I wasted lots of money too.
But my doctor don’t like me asking for meds,he interview me and prescribed.I have asked,but always nothing in return.I have tried tons of antidepressant or antipsychotic…it’s the same for me
It’s difficult to believe that min-101 /roluperidone is a bust. We’ve been talking about it as far as I can remember.
Hey but I got to agree with you.I wanted to quit vaping hence I been researching for supplement.I too have tried different supplement in the past,it did not work out.The reason I am quitting vaping is because it’s making me feel sort of sick,runny nose,mucus and sore throat…really hate the mucus part.Maybe I shall part with the box mod only and use pod system
Weird, I don’t have any issue with vaping except when I inhale too much I cough. I think your problem is that you’re using boxmod which produces too much smoke, try pod vape its healthier and no problems.
I have googled,some people complain of mucus too…yea,I will just ditch the box mod
I dunno, some aspects are looking a lot like Lumateperone’s results at this stage.
“The substantial improvements in the PSP scale with the 64 mg dose are tremendously encouraging. These study results represent a very important outcome in a study of a potential treatment of negative symptoms, one of the most important drivers of everyday disability and a critical unmet medical need for patients with schizophrenia. The consistency in treatment effects, in terms of overall negative symptoms and of the most important subtype, reduced emotional experience, between the previous Phase 2b study and the current one is encouraging. The increased placebo effect from the first to second study seems to be the only reason that the study did not meet its primary endpoint.”
“We are encouraged by the results obtained in this study which expand upon the outcome of the Phase 2b study that showed improvements in the primary endpoint and in multiple secondary endpoints,” said Dr. Remy Luthringer, Executive Chairman and Chief Executive Officer of Minerva. “Even though this study didn’t achieve its primary and key secondary endpoints, primarily due to a larger than expected placebo effect at Week 12, results obtained with the 64 mg dose including the early onset of effect and functional improvement as measured by PSP suggest roluperidone merits continued investigation for the treatment of primary negative symptoms. We intend to consult with the US FDA about the next steps in the development of roluperidone for this indication after we complete the analysis of the study data.
I am not surprised
I don’t think we will ever get a medicinal drug that combats negs and positives without major side effects